Evidence mapPaperPMID 41577803Full record

ArticleNPJ precision oncology2026

An integrated single-cell lung cancer atlas reveals distinct fibroblast phenotypes between adenocarcinoma and squamous cell carcinomas.

Yuta Hirano, Hironori Suzuki, Jun Nakayama, Tomofumi Yamamoto, Eishu Hirata, Jun Araya, Yu Fujita, Yusuke Yamamoto

Abstract read
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuta HiranoLaboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Hironori SuzukiLaboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Jun NakayamaLaboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Tomofumi YamamotoLaboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Eishu HirataDivision of Tumor Cell Biology and Bioimaging, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Jun ArayaDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Yu FujitaDivision of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. yuugot@jikei.ac.jp.
Yusuke YamamotoLaboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan. yuyamamo@ncc.go.jp.

Funding

a Grant-in-Aid for Scientific Research (B) 21H02721, 23K27847, 24K02696, and 25K02414Grant-in-Aid for Challenging Research (Pioneering) 23K17397New Energy and Industrial Technology Development Organization NEDO, 23812437
6 · The paper itself

Abstract

The tumor microenvironment (TME) not only influences cancer progression but also has been shown to have a significant effect on the prognosis. One of the major TME components is cancer-associated fibroblasts (CAFs), of which several subtypes have been identified in tumor tissues. Although single-cell RNA sequencing (scRNA-seq) technology is a powerful tool for investigating the proportions and composition of cells in tissues, large-scale datasets are needed to analyze small cell populations. Here, we constructed an integrated scRNA-seq dataset for non-small cell lung cancer (NSCLC) by compiling publicly available data and observed differences in TME heterogeneity and cellular composition between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). In particular, we identified significant differences in CAF subtypes between LUAD and LUSC. Inflammatory CAFs (iCAFs) were predominantly found in LUAD, whereas myofibroblastic CAFs (mCAFs) were more common in LUSC. A coculture analysis of lung fibroblasts confirmed that LUAD cells induced the iCAF phenotype and, in contrast, that LUSC cells promoted myofibroblastic differentiation. A correlation analysis with the prognosis identified mCAFs as poor prognostic factors in both LUAD and LUSC, but iCAFs were found to be a poor prognostic factor only in LUSC, with the opposite pattern observed in LUAD. This work highlights important considerations regarding the CAF subtype dominance in LUAD and LUSC, which may be related to the prognosis.

Identifiers

PMID41577803
PMCPMC12920623

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.